BCMA/CD3 BsAb Therapy for POEMS Syndrome

Inclusion criteria

• Age ≥ 18 years.
• Diagnosed with POEMS syndrome according to the 2025 Chinese Expert Consensus.
• Deemed suitable for BCMA/CD3 bispecific antibody therapy by the investigator.
• ECOG performance status 0-2.
• Adequate organ function.
• Provided written informed consent.

Exclusion criteria

• Not meeting the diagnostic criteria for POEMS syndrome, including:

• Chronic inflammatory demyelinating polyneuropathy (CIDP),
• MGUS, multiple myeloma, amyloidosis, or other plasma cell disorders not meeting POEMS diagnostic criteria.
• History of prior anti-plasma cell therapy, such as melphalan, cyclophosphamide, proteasome inhibitors, IMiDs, monoclonal antibodies, CAR-T, or bispecific antibodies (except:

• Immunosuppressants used for autoimmune neuropathy;
• Bisphosphonates used for bone disease;
• Topical or low-dose steroids ≤20 mg/day for rheumatic disease).
• Investigator judges the patient unsuitable for BCMA/CD3 bispecific therapy (e.g., severe cardiopulmonary dysfunction).
• Known allergy or intolerance to BCMA/CD3 bispecific antibody or any component.